On the 5th of January 2018 Nordic Biomed Innovation AB and ALTEOGEN Inc. in Daejeon in South Korea joined an MOU. The goal of the MOU is to establish a platform to cooperate in disease diagnostics and product marketing.
ALETOGEN Inc. is a renowned biopharmaceutical company, developing and marketing the next generation long-acting biobetters and biosimilars, e.g. long-acting therapeutic proteins (NeP fusion technology), trastuzumab-drug conjugate, anti-breast cancer therapeutic (NexMab ADC technology) with global networks.
For more information about ALTEOGEN Inc.: www.alteogen.com